Enhertu plus pertuzumab received FDA Priority Review for first-line treatment of HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial results. DESTINY-Breast09 trial showed a 44% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback